Therefore, we only analyzed patients who were refractory or intolerant to standard chemotherapies [FU, OX, IRI, bevacizumab, and anti-EGFR antibody (if the patients had wild type KRAS/ NRAS tumor)] in order to minimalize the inherent bias. This evidence concerns the gene NRAS and neoplasm.